Todd Davis: Third Major Deal of 2025 – Ligand and Medtronic Committed Over $70 million
Todd Davis, Chief Executive Officer and Director at Ligand Pharmaceuticals, shared on LinkedIn:
“We have had several exciting developments at Ligand Pharmaceuticals over the past few months. Yesterday we closed our third major deal of the year with Orchestra BioMed. Ligand and Medtronic committed over $70 million to advance Orchestra’s late-stage partnered cardiology programs: AVIM therapy and Virtue SAB.
These are high-impact, device-based therapies targeting high-risk patient populations with hypertension and arterial disease, two of the most significant global health challenges.
We are thrilled to add these two assets, one of which is backed by Orchestra’s long-term partner Medtronic, to our pipeline of development-stage assets.
Read the announcement here.”
More posts featuring Todd Davis.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023